Table 1.
Clinical characteristics of groups of individuals enrolled for the study.
| Group | HIV− (n = 41) |
HIV+ ART− (n = 33) |
HIV+ ART+ (n = 32) |
|---|---|---|---|
| Age (years) median (IQR) | 34 (27–42) | 35 (28–43) | 41 (35–47) |
| Sex (%females) | 75 | 60 | 100 |
| Time after first positive serology median (IQR) (years) | — | 2.00 (0.42–9.00) (n = 11) or ND (n = 22) | 14.00 (6.75–19.00) |
| Time under ART median (IQR) (years) | — | — | 6.50 (3.00–15.50) |
| Time under ART with documented suppressed VLa median (IQR) (years) | — | — | 3.33 (1.48–5.25) |
| Log10 VLa mean ± SD | — | 4.53 ± 0.95 | <1.70 |
| CD4 countsb median no. of cells/ul (IQR) | 810 (569–989) | 344 (85–568)**** | 564 (432–676)** |
| CD8 countsb median no. of cells/ul (IQR) | 493 (358–665) | 771 (538–1209)** | 739 (597–921)*** |
| CD4/CD8 ratio median (IQR) | 1.62 (1.36–1.92) | 0.36 (0.06–0.56)**** | 0.80 (0.53–1.02)****, ++ |
| %CD4 median (IQR) | 43.00 (40.73–46.50) | 21.38 (10.50–34.5)**** | 31.30 (25.18–37.09)****, ++++ |
ART: antiretroviral treatment. IQR: inter quartile range. ND: not determined. VL: viral load. SD: standard deviation. aVersant HIV-1 RNA 3,0 assay, Siemens. Lower and upper detection limits are 40 and 500.000 RNA copies/mL, respectively (1.7 and 5.7 log). VL supressed: <40 copies/mL. bCD4 and CD8 counts were determined by flow cytometry double platform, FACSCanto, BD, Bioscience. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 comparisons to HIV− group. ++p < 0.01, ++++p < 0.0001 differences between HIV+ ART− and HIV+ ART+ groups.